RT Journal Article
SR Electronic
T1 Longitudinal Changes in Functional Connectivity in Antipsychotic-treated and Antipsychotic-naive Patients with First Episode Psychosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21255375
DO 10.1101/2021.04.13.21255375
A1 Chopra, Sidhant
A1 Francey, Shona M.
A1 O’Donoghue, Brian
A1 Sabaroedin, Kristina
A1 Arnatkeviciute, Aurina
A1 Cropley, Vanessa
A1 Nelson, Barnaby
A1 Graham, Jessica
A1 Baldwin, Lara
A1 Tahtalian, Steven
A1 Yuen, Hok Pan
A1 Allott, Kelly
A1 Alvarez-Jimenez, Mario
A1 Harrigan, Susy
A1 Pantelis, Christos
A1 Wood, Stephen J
A1 McGorry, Patrick
A1 Fornito, Alex
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.04.13.21255375.abstract
AB Background Altered functional connectivity (FC) is a common finding in resting-state functional Magnetic Resonance Imaging (rs-fMRI) studies of people with psychosis, yet how FC disturbances evolve in the early stages of illness, and how antipsychotics may influence the temporal evolution of these disturbances, remains unclear. Here, we scanned first episode psychosis (FEP) patients who were and were not exposed to antipsychotic medication during the first six months of illness at baseline, three months, and 12 months, to characterize how FC changes over time and in relation to medication use.Methods Sixty-two antipsychotic-naïve patients with FEP received either an atypical antipsychotic or a placebo pill over a treatment period of 6 months. Both FEP groups received intensive psychosocial therapy. A healthy control group (n=27) was also recruited. A total of 202 rs-fMRI scans were obtained across three timepoints: baseline, 3-months and 12-months. Our primary aim was to differentiate patterns of FC in antipsychotic-treated and antipsychotic-naive patients within the first 3 months of treatment, and to examine associations with clinical and functional outcomes. A secondary aim was to investigate long-term effects at the 12-month timepoint.Results At baseline, FEP patients showed widespread functional dysconnectivity in comparison to controls, with reductions predominantly affecting interactions between the default mode network (DMN), limbic systems, and the rest of the brain. From baseline to 3 months, patients receiving placebo showed increased FC principally within the same systems, and some of these changes correlated with improved clinical outcomes. Antipsychotic exposure was associated with increased FC primarily between the thalamus and the rest of the brain. At the 12-month follow-up, antipsychotic treatment was associated with a prolonged increase of FC primarily in the DMN and limbic systems.Conclusions and Relevance Antipsychotic-naïve FEP patients show widespread functional dysconnectivity at baseline, followed by an early normalization of DMN and paralimbic dysfunction in patients receiving a psychosocial intervention only. Antipsychotic exposure is associated with distinct FC changes, principally concentrated on thalamo-cortical and limbic networks.Competing Interest StatementJanssen-Cilag partially supported the early years of this study with an unrestricted investigator-initiated grant and provided risperidone, paliperidone and matched placebo for the first 30 participants. The study was then funded by an Australian National Health and Medical Research Project grant (1064704). The funders had no role in study design, data collection, data analysis, data interpretation, writing, approval or submission of this manuscript. SC and AF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. In the past 5 years, CP served on an advisory board for Lundbeck, Australia Pty Ltd. He has received honoraria for talks presented at educational meetings organised by Lundbeck. The authors have declared that there are no other conflicts of interest in relation to the subject of this study.Clinical TrialACTRN12607000608460Funding StatementJanssen-Cilag partially supported the early years of this study with an unrestricted investigator-initiated grant and provided risperidone, paliperidone and matched placebo for the first 30 participants. The study was then funded by an Australian National Health and Medical Research Project grant (1064704). The funders had no role in study design, data collection, data analysis, data interpretation, writing, approval, or submission of this manuscript. SC and AF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. In the past 5 years, CP served on an advisory board for Lundbeck, Australia Pty Ltd. He has received honoraria for talks presented at educational meetings organised by Lundbeck. The authors have declared that there are no other conflicts of interest in relation to the subject of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received ethics approval from the Melbourne Health Human Research and Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided upon request and review by the data governance board.